aztreonam / Generic mfg. - LARVOL DELTA

In vitro microbiological activity of aztreonam, cefepime and cefiderocol combined with nacubactam against NDM-harbouring Escherichia coli and Klebsiella pneumoniae clinical isolates (ESCMID Global 2025) - No abstract available

Late-breaking abstract • Preclinical • Infectious Disease • Pneumonia

Synergistic potential of rifampicin and aztreonam against Pseudomonas aeruginosa biofilm in respiratory infections (ESCMID Global 2025) - No abstract available

Infectious Disease • Respiratory Diseases

Ceftazidime/avibactam plus aztreonam vs cefiderocol in the treatment of infections caused by metallo-beta-lactamase-producing microorganisms: real-world data from the Italian cohort SUSANA (ESCMID Global 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Aztreonam combined with avibactam against Klebsiella pneumoniae: a pharmacokinetically-based approach to MIC determination to improve the prediction of efficacy (ESCMID Global 2025) - No abstract available

Clinical • PK/PD data • Infectious Disease • Pneumonia

Susceptibility of a worldwide collection of 12,613 Enterobacterales isolated during 2021-2023 to the novel combination therapy aztreonam/nacubactam (ESCMID Global 2025) - No abstract available

Combination therapy

Effect of cefepime/enmetazobactam (FEP-META) versus ceftazidime/avibactam (CAZ-AVI) in combination with aztreonam (ATM) against clinical isolates resistant to different β-lactamase classes (ESCMID Global 2025) - No abstract available

Clinical • Combination therapy

In vitro activity of aztreonam/durlobactam against MbetaL-producing Enterobacterales strains (ESCMID Global 2025) - No abstract available

Preclinical

DOT-MGA for rapid determination of susceptibility to ceftazidime/avibactam and aztreonam combination among Enterobacterales (ESCMID Global 2025) - No abstract available

Evaluation of the broth disk elution method for determining the synergistic activity of the aztreonam and ceftazidime-avibactam combination (ESCMID Global 2025) - No abstract available

In vitro activities of aztreonam/nacubactam and cefepime/nacubactam against carbapenemase-producing Enterobacterales collected as part of a global surveillance study in 2021-2022 (ESCMID Global 2025) - No abstract available

Preclinical

Standardising aztreonam/relebactam disk diffusion susceptibility testing in Enterobacterales: a step towards reliable clinical application (ESCMID Global 2025) - No abstract available

Clinical

Synergistic effect of ceftazidime/avibactam with meropenem and aztreonam against carbapenem-resistant Klebsiella pneumoniae (ESCMID Global 2025) - No abstract available

Infectious Disease • Pneumonia

Real world in vitro synergy to doxycycline, ceftriaxone/sulbactam/edetate, and chloramphenicol in ceftazidime/avibactam-resistant, aztreonam synergy-negative isolates from a tertiary referral centre in southern India (ESCMID Global 2025) - No abstract available

Preclinical • Real-world • Real-world evidence

Synergistic effect of ceftazidime/avibactam with aztreonam on carbapenemase-producing Enterobacteriaceae: the ray of hope against NDM (ESCMID Global 2025) - No abstract available

Comparative effectiveness of cefiderocol and ceftazidime/avibactam plus aztreonam against metallo-beta-lactamase-producing Gram-negative isolates (ESCMID Global 2025) - No abstract available

Gram negative • HEOR • Infectious Disease

Ceftazidime/avibactam plus aztreonam vs comparators in metallo-beta-lactamase-producing Enterobacterales: a multicentre target trial emulation (ESCMID Global 2025) - No abstract available

Clinical • Cardiovascular • Infectious Disease • Septic Shock

Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods (ESCMID Global 2025) - No abstract available

Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant E.coli on peritonitis in a pediatric liver transplant recipient (ESCMID Global 2025) - No abstract available

Clinical • Hepatology • Pediatrics • Transplantation

Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales. (PubMed, Antibiotics (Basel)) - "A total of 107 patients were treated with CZA, 63% in monotherapy and 32% with aztreonam (ATM). No difference was observed between death rates (HR 0.86: IC 95% 0.40-1.83), microbiological cure (OR 1.31 IC 95% 0.46-3.67), clinical response (OR 1.39 IC 95% 0.35-5.43), acute kidney injury (OR 0.56 IC 95% 0.11-2.80) or relapse (OR 0.99 IC 95% 0.17-5.51) during the hospitalization after the adjustment. Among adult patients with CRE, no differences were observed between treatments with CZA and BAT after adjustment with IPTW."

Journal • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease

In Vitro Interactions Between Bacteriophages and Antibacterial Agents of Various Classes Against Multidrug-Resistant Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolates. (PubMed, Pharmaceuticals (Basel)) - "Two-fold dilutions of colistin (8-0.125 mg/L), ciprofloxacin, meropenem, aztreonam, and amikacin (256-4 mg/L) were combined with ten-fold dilutions of five different phages (5 × 109-5 × 100 PFU/mL) belonging to Pakpunavirus, Phikzvirus, Pbunavirus, and Phikmvvirus genus. Synergy was observed for most drugs and phages with amikacin, showing strong synergy and reversal of phenotypic resistance against most isolates. Taking into account the wide utility of jumbo phages obtained, the findings of vB_PaerM_AttikonH10 in combination with different classes of antibiotics can enhance the activity of currently ineffective antibiotics against MBL-producing P. aeruginosa isolates."

Journal • Preclinical

Hepatic failure with Providencia rettgeri infection: case report (APASL 2025) - "Furthermore, antimicrobial resistance is one of the important reason to make the pathogen mortal, for example, it resisted to mutiplie antibiotics, like Amikacin, Levofloxacin, Gentamicin, et al. Then bacterial resistance test was tested, and the result showed P. rettgeri was sensitive to amikacin, gentamicin, Tigecycline and Aztreonam. Aztreonam was added to the patient's therapy."

Case report • Clinical • Acute Kidney Injury • Anemia • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Nephrology • Renal Disease • Respiratory Diseases

Evaluation of bacterial skin infections and difference analysis in T lymphocytes and inflammatory factors. (PubMed, Postepy Dermatol Alergol) - "The pathogens and drug resistance: Gram-positive bacteria such as Staphylococcus aureus and β-haemolytic Streptococcus were highly resistant to penicillin, erythromycin, clindamycin, and tetracycline, but sensitive to linezolid and vancomycin. Escherichia coli, Pseudomonas aeruginosa and other Gram-negative bacteria were highly resistant to amoxicillin, ampicillin, aztreonam, ceftriaxone, cefazolin, ciprofloxacin, and sensitive to imipenem...The immune system plays an important regulatory role in the process of infection. T lymphocytes and inflammatory factors are differentially expressed in the process of infection."

Journal • Dermatology • Infectious Disease • Mood Disorders • CD4 • CD8 • IL10 • IL4

Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another? (PubMed, J Antimicrob Chemother) - "In our experience, patients with VIM-producing P. aeruginosa infections treated with ceftazidime-avibactam plus aztreonam mostly achieved clinical success. However, given the limited sample size, further research is required to validate these findings."

Journal • Infectious Disease

Multifaceted quorum-sensing inhibiting activity of 3-(Benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one mitigates Pseudomonas aeruginosa virulence. (PubMed, Virulence) - "Moreover, OZDO in combination with polymyxin B and aztreonam presented a promising avenue for innovative anti-infective therapy. Our study sheds light on the multifaceted potential of OZDO as an anti-virulence agent and its significance in combating P. aeruginosa-associated infections."

Journal • Infectious Disease

Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report. (PubMed, Eur J Clin Microbiol Infect Dis) - "This case highlights both severity of the antimicrobial resistance and hope offered by an under-trial novel antibiotic."

Journal • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis